Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria

  • Technology appraisal guidance
  • TA1010
  • Published: 

Resource impact template

NICE has produced a resource impact template that incorporates the following technology appraisal guidance for paroxysmal nocturnal haemoglobinuria:

  • Iptacopan for treating paroxysmal nocturnal haemoglobinuria (2024) NICE technology appraisal guidance 1000
  • Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (2024) NICE technology appraisal guidance 1010
  • Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (2024) NICE technology appraisal guidance 1019

This page was last updated: